Drug General Information |
Drug ID |
D0Q4VG
|
Former ID |
DNC007267
|
Drug Name |
4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H17ClN2O
|
Canonical SMILES |
CCCCN1C2=C(C=CC=C2Cl)C(=C3C=CC(=O)C=C3)N1
|
InChI |
1S/C17H17ClN2O/c1-2-3-11-20-17-14(5-4-6-15(17)18)16(19-20)12-7-9-13(21)10-8-12/h4-10,19H,2-3,11H2,1H3
|
InChIKey |
FLFPFWKHGXKNNT-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Estrogen receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Estrogen signaling pathway
|
Prolactin signaling pathway
|
Thyroid hormone signaling pathway
|
Endocrine and other factor-regulated calcium reabsorption
|
Proteoglycans in cancer
|
NetPath Pathway
|
FSH Signaling Pathway
|
EGFR1 Signaling Pathway
|
RANKL Signaling Pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Signaling events mediated by HDAC Class II
|
Plasma membrane estrogen receptor signaling
|
LKB1 signaling events
|
Regulation of Telomerase
|
ATF-2 transcription factor network
|
AP-1 transcription factor network
|
FOXM1 transcription factor network
|
Validated nuclear estrogen receptor alpha network
|
Signaling mediated by p38-alpha and p38-beta
|
FOXA1 transcription factor network
|
Reactome
|
Nuclear signaling by ERBB4
|
Nuclear Receptor transcription pathway
|
WikiPathways
|
Estrogen signaling pathway
|
Nuclear Receptors Meta-Pathway
|
Estrogen Receptor Pathway
|
Signaling by ERBB4
|
JAK/STAT
|
Integrated Pancreatic Cancer Pathway
|
Leptin signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
Integrated Breast Cancer Pathway
|
Nuclear Receptors
|
References |
REF 1 | J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. |